TECNOLOGÍA PARA LA MONITORIZACIÓN Y CONTROL DE LA DIABETES

VolverVolver

Resultados 148 resultados LastUpdate Última actualización 07/08/2022 [10:25:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 6 nextPage   por página


Systems and Methods for Risk Based Insulin Delivery Conversion

NºPublicación: US2022246265A1 04/08/2022

Solicitante:

DEXCOM INC [US]

US_2022246264_A1

Resumen de: US2022246265A1

Systems and methods are provided for managing hyperglycemia and hypoglycemia by reconciling incoming data to provide safe and reliable control to range using automatic bolus determination wherein the rate of insulin delivery is dependent on the level of hyperglycemic risk or hypoglycemic risk. Additionally, some implementations are directed to converting insulin delivery into a rate based on glycemic risk.

traducir

BLOOD SUGAR MANAGEMENT DEVICE, BLOOD SUGAR MANAGEMENT SYSTEM, BLOOD SUGAR MANAGEMENT METHOD, AND BLOOD SUGAR MANAGEMENT PROGRAM

NºPublicación: US2022246278A1 04/08/2022

Solicitante:

TERUMO CORP [JP]

CN_114599269_PA

Resumen de: US2022246278A1

A blood sugar management device includes a blood sugar information acquisition unit, a meal information acquisition unit, a storage unit, a blood sugar determination unit, and an information organization unit. When the blood sugar determination unit determines that a measured blood sugar value is within a predetermined range, the information organization unit deletes meal information corresponding to the measured blood sugar value from the storage unit, and when the blood sugar determination unit determines that the measured blood sugar value is not within the predetermined range, the information organization unit holds meal information corresponding to the measured blood sugar value in the storage unit.

traducir

PREDICTION OF BLOOD PERFUSION DIFFICULTIES BASED ON BIOMARKER MONITORING

NºPublicación: US2022241028A1 04/08/2022

Solicitante:

ETHICON LLC [US]

WO_2022157694_A1

Resumen de: US2022241028A1

Blood perfusion difficulty complication(s) may be predicted based on biomarker measurements obtained before a surgery and/or during the surgery via one or more sensing systems. For example, a computing system may monitor the patient biomarker(s) including core body temperature, peripheral temperature, blood sugar level, hydration state data, and/or oxygen saturation data. Based on the prediction, the computing system may generate a control signal configured to alter a matter in which a surgical cutting and stapling device and/or a surgical energy operate, to adjust a surgical procedure plan, to adjust a surgical instrument selection, indicate a probability of the blood perfusion difficulty complication, and/or to indicate a suggested adjustment to surgical procedure plan, surgical approach, and/or surgical instrument selection.

traducir

ANALYTE SENSOR

NºPublicación: US2022240820A1 04/08/2022

Solicitante:

DEXCOM INC [US]

US_2021045665_A1

Resumen de: US2022240820A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

traducir

Systems and Methods for Risk Based Insulin Delivery Conversion

NºPublicación: US2022246264A1 04/08/2022

Solicitante:

DEXCOM INC [US]

US_2022246265_A1

Resumen de: US2022246264A1

Systems and methods are provided for managing hyperglycemia and hypoglycemia by reconciling incoming data to provide safe and reliable control to range using automatic bolus determination wherein the rate of insulin delivery is dependent on the level of hyperglycemic risk or hypoglycemic risk. Additionally, some implementations are directed to converting insulin delivery into a rate based on glycemic risk.

traducir

INTEGRATED MEDICAMENT DELIVERY DEVICE FOR USE WITH CONTINUOUS ANALYTE SENSOR

NºPublicación: US2022245873A1 04/08/2022

Solicitante:

DEXCOM INC [US]

US_2022189086_A1

Resumen de: US2022245873A1

An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and/or via wireless communication.

traducir

SYSTEMS AND METHODS FOR INCORPORATING CO-FORMULATIONS OF INSULIN IN AN AUTOMATIC INSULIN DELIVERY SYSTEM

NºPublicación: US2022241504A1 04/08/2022

Solicitante:

INSULET CORP [US]

US_2022240847_A1

Resumen de: US2022241504A1

Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

traducir

INSULIN STORAGE AND DISPENSING SYSTEM

NºPublicación: US2022241150A1 04/08/2022

Solicitante:

COLGAN JACK WAYNE [US]

Resumen de: US2022241150A1

An insulin storage and dispensing system for housing a standard insulin bottle and securely keeping the bottle in place when using a syringe to access the port on the top of the bottle to fill the syringe while providing accessibility in the form of a convenient mounting assembly for mounting on a refrigerator, an interior cabinet door or wall.

traducir

GLUCOSE LEVEL MANAGEMENT WITHOUT CARBOHYDRATE COUNTING

NºPublicación: US2022241500A1 04/08/2022

Solicitante:

MEDTRONIC MINIMED INC [US]

CN_114822757_PA

Resumen de: US2022241500A1

Disclosed herein are techniques related to glucose level management without carbohydrate counting. The techniques may involve obtaining contextual information for a meal, predicting amounts of glucose to be absorbed into a bloodstream of the patient over a duration of time due to consumption of the meal based on the contextual information for the meal, determining one or more amounts of insulin to counteract effects of the predicted amounts of glucose, and affecting insulin therapy based on outputting information indicative of the determined one or more amounts of insulin.

traducir

AUTOMATED INSULIN DELIVERY SYSTEM USING PRAMLINTIDE

NºPublicación: US2022240847A1 04/08/2022

Solicitante:

INSULET CORP [US]

US_2022241504_A1

Resumen de: US2022240847A1

Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.

traducir

Systems and Methods for Risk Based Insulin Delivery Conversion

NºPublicación: US2022240848A1 04/08/2022

Solicitante:

DEXCOM INC [US]

US_2022246265_A1

Resumen de: US2022240848A1

Systems and methods are provided for managing hyperglycemia and hypoglycemia by reconciling incoming data to provide safe and reliable control to range using automatic bolus determination wherein the rate of insulin delivery is dependent on the level of hyperglycemic risk or hypoglycemic risk. Additionally, some implementations are directed to converting insulin delivery into a rate based on glycemic risk.

traducir

MODEL MOSAIC FRAMEWORK FOR MODELING GLUCOSE SENSITIVITY

NºPublicación: US2022240818A1 04/08/2022

Solicitante:

MEDTRONIC MINIMED INC [US]

Resumen de: US2022240818A1

Methods, systems, and devices for modeling a relationship between glucose sensitivity and a sensor electrical property are described herein. More particularly, the methods, systems, and devices describe partitioning an input signal feature space relating glucose sensitivity and a sensor electrical property into subspaces and training a model for each subspace. For example, the subspace models may form a mosaic of models, for which the output is more accurate than a single model.

traducir

METHOD FOR MANUFACTURING INSERTION GUIDE NEEDLE FOR CONTINUOUS BLOOD GLUCOSE MONITORING DEVICE

NºPublicación: US2022240815A1 04/08/2022

Solicitante:

I SENS INC [KR]

AU_2020326035_PA

Resumen de: US2022240815A1

The present disclosure relates to a method for manufacturing an insertion guide needle for a continuous blood glucose monitoring device. The present disclosure provides a method for manufacturing an insertion guide needle for a continuous blood glucose monitoring device, by which: an insertion guide needle can be manufactured through a cutting process and a bending process of a needle raw plate, so that a complicated manufacturing process is unnecessary, and can thus be easily manufactured through a simple process; an enlargement incision part for continuous enlargement and incision, etc. can be conveniently manufactured through such a simple processing process, so that a manufacturing cost thereof can be reduced and also the size accuracy of the insertion guide needle can be improved; and, particularly, in a process of inserting the insertion guide needle into skin, the insertion guide needle can be brought into point contact with the skin to cut the skin, and then can continuously cut the skin in an enlarged manner, so as to minimize pains which may occur in the process of inserting the insertion guide needle into the skin, thereby alleviating the sense of repulsion or tension at the time of using the continuous blood glucose monitoring device.

traducir

INTERFERENCE REJECTION MEMBRANES USEFUL WITH ANALYTE SENSORS

NºPublicación: US2022240823A1 04/08/2022

Solicitante:

MEDTRONIC MINIMED INC [US]

Resumen de: US2022240823A1

Embodiments of the invention provide amperometric analyte sensors having optimized elements such as interference rejection membranes, and associated architectures, as well as methods for making and using such sensors. While embodiments of the innovation can be used in a variety of contexts, typical embodiments of the invention include glucose sensors used in the management of diabetes.

traducir

SYSTEM AND METHOD FOR WEARABLE MEDICAL SENSOR AND NEURAL NETWORK BASED DIABETES ANALYSIS

NºPublicación: US2022240864A1 04/08/2022

Solicitante:

UNIV PRINCETON [US]

WO_2020257158_A1

Resumen de: US2022240864A1

According to various embodiments, a machine-learning based system for diabetes analysis is disclosed. The system includes one or more processors configured to interact with a plurality of wearable medical sensors (WMSs). The processors are configured to receive physiological data from the WMSs and demographic data from a user interface. The processors are further configured to train at least one neural network based on a grow-and-prune paradigm to generate at least one diabetes inference model. The neural network grows at least one of connections and neurons based on gradient information and prunes away at least one of connections and neurons based on magnitude information. The processors are also configured to output a diabetes-based decision by inputting the received physiological data and demographic data into the generated diabetes inference model.

traducir

DOSAGE RECOMMENDATION FACILITATED BY ARTIFICIAL INTELLIGENCE

NºPublicación: US2022241501A1 04/08/2022

Solicitante:

MEDTRONIC MINIMED INC [US]

Resumen de: US2022241501A1

Disclosed herein are techniques related to glucose level management without carbohydrate counting. The techniques may involve obtaining contextual information for a meal, predicting amounts of glucose to be absorbed into a bloodstream of the patient over a duration of time due to consumption of the meal based on the contextual information for the meal, determining one or more amounts of insulin to counteract effects of the predicted amounts of glucose, and affecting insulin therapy based on outputting information indicative of the determined one or more amounts of insulin.

traducir

MODEL MOSAIC FRAMEWORK FOR MODELING GLUCOSE SENSITIVITY

NºPublicación: WO2022165136A1 04/08/2022

Solicitante:

MEDTRONIC MINIMED INC [US]

Resumen de: WO2022165136A1

Methods, systems, and devices for modeling a relationship between glucose sensitivity and a sensor electrical property are described herein. More particularly, the methods, systems, and devices describe partitioning an input signal feature space relating glucose sensitivity and a sensor electrical property into subspaces and training a model for each subspace. For example, the subspace models may form a mosaic of models, for which the output is more accurate than a single model.

traducir

AUTOMATED INSULIN DELIVERY SYSTEM USING PRAMLINTIDE

NºPublicación: WO2022164738A1 04/08/2022

Solicitante:

INSULET CORP [US]

US_2022241504_A1

Resumen de: WO2022164738A1

Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.

traducir

INTERFERENCE REJECTION MEMBRANES USEFUL WITH ANALYTE SENSORS

NºPublicación: WO2022164981A1 04/08/2022

Solicitante:

MEDTRONIC MINIMED INC [US]

US_2022240823_A1

Resumen de: WO2022164981A1

Embodiments of the invention provide amperometric analyte sensors having optimized elements such as interference rejection membranes, and associated architectures, as well as methods for making and using such sensors. The interference rejection membranes are made by photopolymerisation of a reaction mixture comprising a monomer such as methacrylate, a crosslinker such as ethylene glycole or silane and a diazo photoinitiator. While embodiments of the innovation can be used in a variety of contexts, typical embodiments of the invention include glucose sensors used in the management of diabetes.

traducir

SYSTEMS AND METHODS FOR INCORPORATING CO-FORMULATIONS OF INSULIN IN AN AUTOMATIC INSULIN DELIVERY SYSTEM

NºPublicación: WO2022164737A1 04/08/2022

Solicitante:

INSULET CORP [US]

US_2022241504_A1

Resumen de: WO2022164737A1

Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

traducir

SYSTEMS AND METHODS FOR AUTOMATED INSULIN DELIVERY FOR DIABETES THERAPY

NºPublicación: WO2022165518A1 04/08/2022

Solicitante:

TANDEM DIABETES CARE INC [US]

US_2022233773_A1

Resumen de: WO2022165518A1

Disclosed herein are systems and methods for automated insulin delivery that reduce a risk of hypoglycemia from automatically delivering correction boluses. Rather than automatically delivering a correction bolus when a current or future predicted glucose level of a user is over a high glucose threshold, the system can review additional factors to determine whether an automatic correction bolus is appropriate. For example, the system can be prevented from delivering an automatic correction bolus if the user's glucose levels are falling at greater than a predetermined rate and/or if a current glucose level is greater than a future predicted glucose level even if the user's current or predicted future glucose levels is over the high threshold.

traducir

INSERTION DEVICE WITH LINKAGE ASSEMBLY

NºPublicación: EP4035707A1 03/08/2022

Solicitante:

MEDTRONIC MINIMED INC [US]

CN_114832182_PA

Resumen de: EP4035707A1

An insertion device configured to implant a first medical device and a second medical device in a user. The first medical device may be a fluid delivery cannula configured to deliver a fluid (e.g., insulin) to the user. The second medical device may be an analyte sensor (e.g., a glucose sensor) configured to detect a physiological characteristic of the user (e.g., a glucose level). The insertion device may be configured to be worn by the user. The insertion device includes a first linkage assembly configured to extend and retract a first insertion needle to implant the first medical device and a second linkage assembly configured to extend and retract a second insertion needle to implant the second medical device. The insertion device includes a user input device configured to cause the insertion device to initiate the implantation when activated by the user.

traducir

AUTOMATIC DRUG DELIVERY SYSTEM FOR DELIVERY OF A GLP-1 THERAPEUTIC

NºPublicación: EP4036934A1 03/08/2022

Solicitante:

INSULET CORP [US]

US_2022241504_A1

Resumen de: EP4036934A1

The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal dosing of GLP-1 or co-formulation of GLP-1 and insulin. The size and frequency of the basal doses may be controlled by a medication delivery algorithm resident on the wearable drug delivery device based on a basal dosing history and readings from a continuous glucose monitor monitoring the glucose levels of the wearer of the device.

traducir

ONBOARDING AND TOTAL DAILY INSULIN ADAPTIVITY

NºPublicación: EP4035174A1 03/08/2022

Solicitante:

INSULET CORP [US]

AU_2020354476_PA

Resumen de: WO2021061711A1

Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.

traducir

MICRO MODELS AND LAYERED PREDICTION MODELS FOR ESTIMATING SENSOR GLUCOSE VALUES AND REDUCING SENSOR GLUCOSE SIGNAL BLANKING

Nº publicación: WO2022159321A2 28/07/2022

Solicitante:

MEDTRONIC MINIMED INC [US]

Resumen de: WO2022159321A2

Methods, systems, and devices for improving continuous glucose monitoring ("CGM") are described herein. More particularly, the methods, systems, and devices describe applying layered machine learning models to generate predicted sensor glucose values. The system may use the predicted sensor glucose values to display a sensor glucose value to a user. The layered models may generate more reliable sensor glucose predictions across many scenarios, leading to a reduction of sensor glucose signal blanking. The methods, systems, and devices described herein further comprise applying a plurality of micro model to estimate sensor glucose values under outlier conditions. The system may prioritize the models that are trained for certain outlier conditions when the system detects those outlier condition based on the sensor data.

traducir

Página1 de 6 nextPage por página

punteroimgVolver